Sırma Ekmekci Sema, Emrence Zeliha, Abacı Neslihan, Sarıman Melda, Salman Burcu, Ekmekci Cumhur Gökhan, Güleç Çağrı
İstanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Genetics, İstanbul, Turkey
Turk J Haematol. 2020 Nov 19;37(4):226-233. doi: 10.4274/tjh.galenos.2020.2020.0144. Epub 2020 Jun 26.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease resulting from the accumulation of genetic changes that affect the development of T-cells. The precise role of lymphoid enhancer-binding factor 1 () in T-ALL has been controversial since both overexpression and inactivating mutations have been reported to date. Here, we investigate the potential gene targets of in the Jurkat human T-cell leukemia cell line.
We used small interfering RNA (siRNA) technology to knock down in Jurkat cells and then compared the gene expression levels in the knockdown cells with non-targeting siRNA-transfected and non-transfected cells by employing microarray analysis.
We identified , a tumor suppressor gene, as the most significantly downregulated gene in knockdown cells, and we further confirmed its downregulation by real-time quantitative polymerase chain reaction (qRT-PCR) in mRNA and at protein level by western blotting.
Our results revealed that is positively regulated by in Jurkat cells, which indicates the capability of as a tumor suppressor and, together with previous reports, suggests that exhibits a regulatory role in T-ALL via not only its oncogenic targets but also tumor suppressor genes.
T 细胞急性淋巴细胞白血病（T-ALL）是一种侵袭性疾病，由影响 T 细胞发育的基因变化积累所致。淋巴样增强子结合因子 1（LEF1）在 T-ALL 中的精确作用一直存在争议，因为迄今为止既有过表达的报道，也有失活突变的报道。在此，我们研究 Jurkat 人 T 细胞白血病细胞系中 LEF1 的潜在基因靶点。
我们使用小干扰 RNA（siRNA）技术敲低 Jurkat 细胞中的 LEF1，然后通过微阵列分析比较 LEF1 敲低细胞与非靶向 siRNA 转染细胞及未转染细胞中的基因表达水平。
我们确定肿瘤抑制基因[此处原文缺失该基因名称]为 LEF1 敲低细胞中下调最显著的基因，并通过实时定量聚合酶链反应（qRT-PCR）在 mRNA 水平以及通过蛋白质印迹在蛋白质水平进一步证实了其下调。
我们的结果表明，在 Jurkat 细胞中 LEF1 对[此处原文缺失该基因名称]起正向调节作用，这表明[此处原文缺失该基因名称]具有肿瘤抑制能力，并且与先前的报道一起表明，LEF1 在 T-ALL 中不仅通过其致癌靶点，还通过肿瘤抑制基因发挥调节作用。
